EDO MED

EDO Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation oncology treatments for patients with limited therapeutic options. The company's lead candidate, tinostamustine (EDO-S101), is a first-in-class fusion molecule that combines an alkylating agent with a histone deacetylase (HDAC) inhibitor to improve efficacy and overcome resistance in hematologic and solid tumors. EDO Therapeutics operates as part of the Mundipharma network, leveraging global resources to advance its pipeline through clinical development. Their research emphasizes synergistic mechanisms of action to target difficult-to-treat cancers like peripheral T-cell lymphoma and glioblastoma. The company's pipeline also includes antibody-drug conjugates and novel small molecules designed to address significant unmet needs in oncology.